ArticleCancer chemotherapy and pharmacology2010
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paul K Paik et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this papertrialcites it